The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Nov. 28, 11:01 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #58. Clovis Oncology EOS (Ethical Oncology Science) S.p.A.

Acquirer: Clovis Oncology (NASDAQ:CLVS)
Acquiree: EOS (Ethical Oncology Science) S.p.A.
Details: Clovis Oncology (NASDAQ:CLVS) announced today that it has acquired EOS (Ethical Oncology Science) S.p.A., a privately-held Italian biopharmaceutical company developing a novel targeted therapy to treat cancer. EOS owns the exclusive global (excluding China) development and commercialization rights for lucitanib, an oral, dual-selective inhibitor of the tyrosine kinase activity of fibroblast growth factor (FGF) receptors 1 and 2 (FGFR1/2) and vascular endothelial growth factor (VEGF) receptors 1-3 (VEGFR1-3). In 2012, EOS sublicensed lucitanib rights in Europe and the rest-of-world (ROW) markets, excluding China, to Les Laboratoires Servier (Servier). Clovis holds exclusive rights for lucitanib in the U.S. and Japan, and will collaborate with Servier on the global clinical development of lucitanib.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. Co. markets Rubraca®, which is an oral small molecule inhibitor of poly ADP-ribose polymerase for indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Co.'s product candidates include: FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein; and Lucitanib, an oral potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1 through 3.

Open the CLVS Page at The Online Investor »

Company Name: 
Clovis Oncology Inc
Drugs & Pharmaceuticals
Number of ETFs Holding CLVS: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the CLVS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CLVS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Sell (1.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
CLVS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 58 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.